Identification of a Consolidation Phase in Immunological Memory.
antibody
boost
primary response
secondary response
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
10
2018
accepted:
25
02
2019
entrez:
4
4
2019
pubmed:
4
4
2019
medline:
10
9
2020
Statut:
epublish
Résumé
Long lasting antibody responses and immunological memory are the desired outcomes of vaccination. In general, multiple vaccine doses result in enhanced immune responses, a notable exception being booster-induced hyporesponsiveness, which has been observed with polysaccharide and glycoconjugate vaccines. In this study, we analyzed the effect of early booster doses of multimeric protein vaccine (1-11)E2 on recall memory to B epitope 1-11 of β-amyloid. Mice immunized with a single dose of (1-11)E2 stochastically display, when immunized with a recall dose 9 months later, either memory, i.e., an enhanced response to epitope 1-11, or hyporesponsiveness, i.e., a reduced response. Memory is the most common outcome, achieved by 80% of mice. We observed that a booster dose of vaccine (1-11)E2 at day 15 significantly reduced the ratio between the magnitude of the secondary and primary response, causing an increase of hyporesponsive mice. This booster-dependent disruption of recall memory only occurred in a limited time window: a booster dose at day 21 had no significant effect on the ratio between the secondary and primary response magnitude. Thus, this study identifies a consolidation phase in immunological memory, that is a time window during which the formation of memory is vulnerable, and a disrupting stimulus reduces the probability that memory is achieved.
Identifiants
pubmed: 30941140
doi: 10.3389/fimmu.2019.00508
pmc: PMC6433959
doi:
Substances chimiques
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
508Références
Nature. 1999 Jul 8;400(6740):173-7
pubmed: 10408445
Pediatr Infect Dis J. 2001 Jan;20(1):63-75
pubmed: 11176570
Nat Rev Immunol. 2006 Oct;6(10):741-50
pubmed: 16977339
Pediatr Infect Dis J. 2007 Aug;26(8):716-22
pubmed: 17848884
Mol Immunol. 2008 Feb;45(4):1056-62
pubmed: 17850871
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
J Exp Med. 2009 Dec 21;206(13):2907-14
pubmed: 19934021
Nat Immunol. 2010 Aug;11(8):681-8
pubmed: 20644574
Immunity. 2010 Oct 29;33(4):451-63
pubmed: 21029957
Immunol Cell Biol. 2011 Jul;89(5):604-9
pubmed: 21102534
Science. 2011 Mar 4;331(6021):1203-7
pubmed: 21310965
Expert Rev Vaccines. 2011 Mar;10(3):307-22
pubmed: 21434799
Nat Immunol. 2011 Jun;12(6):509-17
pubmed: 21739679
Science. 2012 Jan 20;335(6066):338-41
pubmed: 22223740
Comput Math Methods Med. 2012;2012:842329
pubmed: 22997539
PLoS One. 2013 Sep 12;8(9):e72588
pubmed: 24069152
Vaccine. 2014 May 23;32(25):2948-57
pubmed: 24709587
PLoS One. 2014 Jul 01;9(7):e101474
pubmed: 24983378
Biomol Concepts. 2012 Oct;3(5):479-86
pubmed: 25436552
Nat Rev Immunol. 2015 Mar;15(3):137-48
pubmed: 25656706
Nat Rev Immunol. 2015 Mar;15(3):160-71
pubmed: 25698678
Immunity. 2016 Jan 19;44(1):116-130
pubmed: 26795247
Nat Rev Immunol. 2016 Feb;16(2):124-8
pubmed: 26831526
BMC Microbiol. 2016 Jul 16;16(1):152
pubmed: 27421762
Curr Opin Immunol. 2017 Apr;45:112-118
pubmed: 28319730
J Immunol. 2017 Aug 15;199(4):1301-1307
pubmed: 28687657